A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : OCCC / ovarian clear cell carcinoma

[Related PubMed/MEDLINE]
Total Number of Papers: 158
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   OCCC  (>> Co-occurring Abbreviation)
Long Form:   ovarian clear cell carcinoma
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Clinical Characteristics of Clear Cell Ovarian Cancer: A Retrospective Multicenter Experience of 308 Patients in South Korea. OS, RFS
2020 Cysteine deprivation targets ovarian clear cell carcinoma via oxidative stress and iron-sulfur cluster biogenesis deficit. ---
2020 Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma. HGSOC
2020 Effect of Chemotherapy, Laparoscopy, and Cytology on Stage IC Ovarian Clear Cell Carcinoma: A Long-Term, Single-Center Study. OS, PFS
2020 EMT-inducing transcription factor ZEB1-associated resistance to the BCL-2/BCL-XL inhibitor is overcome by BIM upregulation in ovarian clear cell carcinoma cells. EMT
2020 Endometriosis-associated ovarian cancer is not a distinct clinical entity among young patients: A 12-year cohort study. EAOC, OEC, OS, PFS
2020 High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy. ER, GPC3
2020 Metastatic Ovarian Clear Cell Carcinoma in the Context of In Vitro Fertilization Pregnancy. IVF
2020 Precision medicine for ovarian clear cell carcinoma based on gene alterations. ---
10  2020 Recurrence Patterns and Survival Outcomes in Chinese Patients with Surgically Treated Recurrent Ovarian Clear Cell Carcinoma: A Single Institutional Analysis of 45 Cases. OS, PRS
11  2020 Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma. EOC
12  2020 The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis. C3aR, C5aR, EOC, GEO, GO
13  2020 Translational genomics of ovarian clear cell carcinoma. ---
14  2019 Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes. EOC, PFS
15  2019 Association of the hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms with prognosis in ovarian clear cell carcinoma. HIF-1alpha, SNPs
16  2019 Brain metastasis from ovarian clear cell carcinoma: A case report. BM, EOC
17  2019 Clinicopathological correlation of ARID1A status with HDAC6 and its related factors in ovarian clear cell carcinoma. HDAC, HIF-1alpha, HR, PD-L1
18  2019 Current Position of the Molecular Therapeutic Targets for Ovarian Clear Cell Carcinoma: A Literature Review. ---
19  2019 HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer. HDAC6
20  2019 Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors. PGRN
21  2019 Long non-coding RNA SNHG6 promotes cell proliferation and migration through sponging miR-4465 in ovarian clear cell carcinoma. ceRNA, EZH2, SNHG6
22  2019 Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma. PDX
23  2019 Management and clinical outcomes of patients with recurrent/progressive ovarian clear cell carcinoma. CSS, PFI, SAR
24  2019 Multiregion whole-genome sequencing depicts intratumour heterogeneity and punctuated evolution in ovarian clear cell carcinoma. ---
25  2019 Ovarian Clear Cell Carcinoma Detected During Long-Term Management of Endometriotic Cysts in Young Patients: Possible Heterogeneity of this Tumor. ---
26  2019 Ovarian Clear Cell Carcinoma in Cowden Syndrome. CS
27  2019 Overexpression of IGF2BP3 as a Potential Oncogene in Ovarian Clear Cell Carcinoma. ---
28  2019 Prognostic value of lymph nodes ratio in patients with stage III ovarian clear cell carcinoma: A retrospective study of patients in Southwest China. LNR, OS, PFS
29  2019 Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. NLR, OS, PLR, SIR
30  2019 Resibufogenin inhibits ovarian clear cell carcinoma (OCCC) growth in vivo, and migration of OCCC cells in vitro, by down-regulating the PI3K/AKT and actin cytoskeleton signaling pathways. qPCR, TUNEL
31  2019 Survival Following Chemotherapy in Ovarian Clear Cell Carcinoma Is Not Associated with Pathological Misclassification of Tumor Histotype. HGSOC, OS, PFS
32  2019 The histone methyltransferase WHSC1 is regulated by EZH2 and is important for ovarian clear cell carcinoma cell proliferation. EZH2, WHSC1
33  2019 Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma. ---
34  2018 A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium. PFS
35  2018 Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes. OS
36  2018 ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. ARID1A, ARID1B
37  2018 Characterization and drug sensitivity of a novel human ovarian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor. LOH
38  2018 Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort. ---
39  2018 Distinguishing the progression of an endometrioma: Benign or malignant? IHC
40  2018 Endometriosis does not confer improved prognosis in ovarian clear cell carcinoma: a retrospective study at a single institute. CI, FIGO, HR, OS, PFS
41  2018 Everolimus following 5-aza-2-deoxycytidine is a promising therapy in paclitaxel-resistant clear cell carcinoma of the ovary. 5-aza-dC
42  2018 Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. EMS-OCCC, NGS, WES
43  2018 Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma. HGSC, HR, HRD, LOH, LST, TAI
44  2018 Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. ---
45  2018 Identification of potential key genes associated with ovarian clear cell carcinoma. DEGs, PPI, RT-PCR
46  2018 Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing. ---
47  2018 Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma. iASPP, PLK
48  2018 Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma. ---
49  2018 Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma? CI, CRS, HR, OS
50  2018 Morphologic and Immunohistochemical Study of Clear Cell Carcinoma of the Uterine Endometrium and Cervix in Comparison to Ovarian Clear Cell Carcinoma. CCAC, ECCC, HNF
51  2018 Outcomes of ovarian clear cell carcinoma (OCCC) of the Vall d'Hebron Hospital/Vall d'Hebron Institute of Oncology (VHIO). VHIO
52  2018 PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. ddPCR
53  2018 Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma. LMR, NLR, OS, PFS, PLR, ROC, SIR
54  2018 Prognostic Value of Serum CA19-9 and Perioperative CA-125 Levels in Ovarian Clear Cell Carcinoma. CA125, CA19-9, HR, OS, RFS, RFS
55  2018 Significance of Ovarian Endometriosis on the Prognosis of Ovarian Clear Cell Carcinoma. DFS, OS
56  2018 Somatic copy number alterations have prognostic impact in patients with ovarian clear cell carcinoma. CGH, OS, PFS
57  2018 The Tumor Suppressor ARID1A Controls Global Transcription via Pausing of RNA Polymerase II. RNAPII
58  2018 Therapeutic significance of full lymphadenectomy in early-stage ovarian clear cell carcinoma. CI, DSS, HR, LNM, PAND, PLND
59  2017 An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. OS, PFS, SOC
60  2017 APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner. ---
61  2017 Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options. CGP, CRGA
62  2017 Could fertility-sparing surgery be considered for women with early stage ovarian clear cell carcinoma? BSO, CSS, FSS, OP, OS, SEER
63  2017 Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. ARID1A
64  2017 Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer. EOC, HGSOC, IHC, MV TF, TF
65  2017 Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer. ARID1A, LNM, OEAC, OS
66  2017 Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma. FIGO, OEC, PAR2
67  2017 Identification of novel mutations in Japanese ovarian clear cell carcinoma patients using optimized targeted NGS for clinical diagnosis. FF, FFPE, NGS
68  2017 Inhibition of Aurora Kinase A Synergistically Enhances Cytotoxicity in Ovarian Clear Cell Carcinoma Cell Lines Induced by Cisplatin: A Potential Treatment Strategy. Aurora-A
69  2017 Is adjuvant chemotherapy beneficial for surgical stage I ovarian clear cell carcinoma? ACG, DSS
70  2017 MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. DCLK1, EMT, miR-424
71  2017 Ovarian Clear Cell Carcinoma Sub-Typing by ARID1A Expression. ARID1A
72  2017 Prognostic impact of interleukin-6 expression in stage I ovarian clear cell carcinoma. OS
73  2017 Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma. NLR, OS, PFS, SIS
74  2017 Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. HR, OS, PD-1, PD-L1, PFS, PR
75  2017 Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma. STAT3
76  2017 The frequency of neoantigens per somatic mutation rather than overall mutational load or number of predicted neoantigens per se is a prognostic factor in ovarian clear cell carcinoma. PFS
77  2017 Three versus six cycles of adjuvant platinum-based chemotherapy in early stage clear cell ovarian carcinoma - A multi-institutional cohort. CI, HR, OS, PFS
78  2017 Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. CI, OS, PI3K, RTK, SWI/SNF
79  2017 [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma]. AURKA, BRCA1, EGFR, HER2, PD-L1, SCS
80  2016 ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin. ARID1A, siRNA
81  2016 c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. EOCs, PDX
82  2016 Cytomorphology of ovarian clear cell carcinomas in peritoneal effusions. FIGO
83  2016 Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. GPC3
84  2016 Expressions of CD44,CD47,and c-met in Ovarian Clear Cell Carcinoma and Their Clinical Significance. ---
85  2016 Functional redundancy of the Notch pathway in ovarian cancer cell lines. Dll, HDACIs, Hes, OSC
86  2016 HNF1beta drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). BSO, GCLC, HNF1beta, OSC
87  2016 Loss of HDAC-Mediated Repression and Gain of NF-kappaB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer. ---
88  2016 MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma. HGSC, miRNA
89  2016 Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients. ---
90  2016 Prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma: Experiences at three academic institutions. EAOC, LVSI, OS, RFS
91  2016 Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary. LN
92  2016 Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib. SL
93  2016 Systemic Inflammatory Response Markers and CA-125 Levels in Ovarian Clear Cell Carcinoma: A Two Center Cohort Study. CA125, CI, CR, MLR, NLR, PFS, PLR, SIR
94  2016 Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma. ---
95  2016 The Application Value of HNF-1beta Transcription Factor in the Diagnosis of Ovarian Clear Cell Carcinoma. ---
96  2016 The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma. CT, OS, PFS, RT
97  2016 [Perspectives of Individualized Treatment by Genome-Wide Analyses in Ovarian Cancer]. HGSOC
98  2015 Annexin A4 and cancer. Anxa4, BC, CRC, EC, ESCC, GC, HCC, LC, MM, MSGT, OSCC, PCa, PCC, RCC
99  2015 Are clear cell carcinomas of the ovary and endometrium phenotypically identical? A proteomic analysis. ECCC
100  2015 Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. ---